HIK.L
Hikma Pharmaceuticals
Health Care · Pharmaceuticals · LSE
$1,463.00
Data: 2026-05-09
✓ ETHICAL PASS
Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$3.0B
Total market value of the company
Rev Growth
+8.5%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Hikma Pharmaceuticals
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
28.3% PASS
Debt must be below 33% of total assets
Cash Ratio
3.8% PASS
Interest-bearing cash below 33% of assets
Receivables
17.6% PASS
Receivables below 49% of assets
Revenue Purity
2.7% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
AVOID
Overall assessment combining ethics, valuation, and quality
Ethical Score
76.6
Valuation Score
72.5
Quality Score
49.0
Combined
67.2
Trading at $1418, 174% above fair value of $517. Passes all ethical screens. Ranks better than 44% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-11.8%
Historical annualised return based on price data
Days in State
21
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-08 | Hikma Pharmaceuticals PLC | 118,300 | $2,281,888 | ||
| 2026-05-07 | Hikma Pharmaceuticals PLC | 116,988 | $2,249,562 | ||
| 2026-05-06 | Hikma Pharmaceuticals PLC | 62,430 | $1,219,257 | ||
| 2026-05-05 | Hikma Pharmaceuticals PLC | 90,471 | $1,735,686 | ||
| 2026-05-05 | Hill (Julie) | 178 | $3,398 | ||
| 2026-05-05 | Ringdal (Susan) | 2,337 | $44,613 | ||
| 2026-05-05 | Arkhagha (Hussein) | 407 | $7,769 | ||
| 2026-05-01 | Hikma Pharmaceuticals PLC | 94,669 | $1,802,687 | ||
| 2026-04-30 | Hikma Pharmaceuticals PLC | 101,001 | $1,905,181 | ||
| 2026-04-29 | Hikma Pharmaceuticals PLC | 88,131 | $1,651,663 |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09